Clinical Trial Update: Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dalpiciclib in combination with fulvestrant and compound gossyfol acetate tablets for women with HR-positive, HER2-negative metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Fulvestrant (fulvestrant)
• compound gossyfol acetate (not specified)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed | Phase 2 | Status: UNKNOWN